Agios Pharmaceuticals (NASDAQ:AGIO) Sees Large Volume Increase – Should You Buy?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares saw unusually-strong trading volume on Monday . Approximately 342,761 shares were traded during trading, a decline of 43% from the previous session’s volume of 599,397 shares.The stock last traded at $33.25 and had previously closed at $32.19.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Royal Bank of Canada raised their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 10th. Scotiabank raised their target price on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Leerink Partnrs lowered Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 27th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Agios Pharmaceuticals presently has an average rating of “Hold” and an average target price of $56.33.

Agios Pharmaceuticals Price Performance

The business’s 50-day simple moving average is $47.15 and its two-hundred day simple moving average is $45.63. The stock has a market cap of $2.05 billion, a price-to-earnings ratio of 3.16 and a beta of 0.87.

Insiders Place Their Bets

In related news, insider Tsveta Milanova sold 2,804 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the sale, the insider now directly owns 18,906 shares in the company, valued at $608,395.08. This represents a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 4.93% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Caxton Associates LP increased its position in shares of Agios Pharmaceuticals by 0.7% during the second quarter. Caxton Associates LP now owns 37,453 shares of the biopharmaceutical company’s stock worth $1,615,000 after buying an additional 264 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in Agios Pharmaceuticals by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 363 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Agios Pharmaceuticals by 6.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,132 shares of the biopharmaceutical company’s stock worth $539,000 after purchasing an additional 688 shares during the period. Acadian Asset Management LLC bought a new position in shares of Agios Pharmaceuticals during the 2nd quarter worth approximately $37,000. Finally, Quest Partners LLC acquired a new stake in shares of Agios Pharmaceuticals during the 2nd quarter worth approximately $40,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.